Baxter International Inc (NYSE:BAX) SVP Scott Pleau sold 27,197 shares of the firm’s stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $73.57, for a total value of $2,000,883.29. Following the transaction, the senior vice president now owns 47,363 shares of the company’s stock, valued at $3,484,495.91. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
BAX stock opened at $73.80 on Friday. The company has a current ratio of 2.63, a quick ratio of 2.03 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $39.17 billion, a price-to-earnings ratio of 29.76, a P/E/G ratio of 1.89 and a beta of 0.81. Baxter International Inc has a 1 year low of $58.81 and a 1 year high of $75.62.
Baxter International (NYSE:BAX) last issued its earnings results on Thursday, April 26th. The medical instruments supplier reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.08. Baxter International had a return on equity of 15.70% and a net margin of 7.75%. The business had revenue of $2.68 billion for the quarter, compared to analyst estimates of $2.62 billion. During the same quarter last year, the company earned $0.58 EPS. The business’s quarterly revenue was up 8.2% on a year-over-year basis. equities analysts forecast that Baxter International Inc will post 2.89 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, July 2nd. Stockholders of record on Friday, June 1st will be given a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, May 31st. This is a positive change from Baxter International’s previous quarterly dividend of $0.16. Baxter International’s dividend payout ratio (DPR) is 30.65%.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Drexel Morgan & Co. raised its position in shares of Baxter International by 18.4% during the 1st quarter. Drexel Morgan & Co. now owns 4,887 shares of the medical instruments supplier’s stock worth $318,000 after acquiring an additional 760 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Baxter International by 0.5% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 185,750 shares of the medical instruments supplier’s stock worth $11,508,000 after acquiring an additional 900 shares in the last quarter. Rational Advisors LLC raised its position in shares of Baxter International by 28.5% during the 1st quarter. Rational Advisors LLC now owns 4,375 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 970 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in shares of Baxter International by 0.7% during the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 136,158 shares of the medical instruments supplier’s stock worth $8,856,000 after acquiring an additional 990 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its position in shares of Baxter International by 1.3% during the 1st quarter. Mn Services Vermogensbeheer B.V. now owns 77,105 shares of the medical instruments supplier’s stock worth $5,015,000 after acquiring an additional 1,000 shares in the last quarter. 83.44% of the stock is currently owned by institutional investors and hedge funds.
BAX has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a report on Thursday, May 17th. ValuEngine upgraded Baxter International from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Finally, Bank of America increased their price target on Baxter International from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Tuesday, May 22nd. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $73.25.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.